Juleen Gayed

Marlow, ENG SL71YL, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study.

Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study.

Journal: Vaccines

Published: April 03, 2026

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.

Journal: Infectious diseases and therapy

Published: January 23, 2026

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results).

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results).

Journal: Vaccines

Published: January 22, 2026

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.

Journal: Infectious diseases and therapy

Published: March 07, 2025

Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years Old.

Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years Old.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 06, 2025

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 06, 2025

A Response to: Letter to the Editor Regarding "Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination".

A Response to: Letter to the Editor Regarding "Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination".

Journal: Infectious diseases and therapy

Published: February 21, 2025

A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.

A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.

Journal: Vaccine

Published: September 30, 2024

Design and rationale of the COVID vaccine-associated myocarditis/pericarditis (CAMP) study.

Design and rationale of the COVID vaccine-associated myocarditis/pericarditis (CAMP) study.

Journal: American heart journal

Published: June 10, 2024

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.

Journal: Vaccines

Published: May 03, 2024

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.

Journal: Vaccines

Published: December 19, 2023

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.

Journal: Infectious diseases and therapy

Published: November 13, 2023

Showing 1-12 of 14

Last Updated: 09/26/2026